Work Here?
Overview
Gerresheimer creates specialized packaging and drug delivery devices for the pharmaceutical and biotech industries. Its offerings include packaging solutions and device components for medicines, such as inhalers and insulin pens, as well as complex drug delivery systems. The company works by designing, engineering, and manufacturing these components to meet strict pharma quality and regulatory standards, serving as a global partner to pharma and biotech customers. It differentiates itself by shifting from consumer glass products to focused, high-spec packaging and device solutions for pharma and cosmetics, building its business around close collaboration with customers and end-to-end support. The goal is to help pharmaceutical and biotech companies bring safe, reliable, and scalable packaging and delivery technologies to market across the globe.
About Gerresheimer
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Düsseldorf, Germany
Founded
1864
Get referred to Gerresheimer
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 30, 2026 preliminaries showed Q2 revenue €578 million and EBITDA €102 million.
- The July 29, 2026 Apax deal should cut leverage and strengthen financing flexibility.
- July 24, 2026 Zhenjiang and June 2026 Peachtree City expansions add capacity for China and U.S. demand.
What critics are saying
- BaFin accounting findings and 2025 restatements signal internal-control failures, threatening 2027 credibility.
- Interim CEO turnover on August 24, 2026 shows leadership instability during restructuring.
- Centor and PPP divestitures can strip scale; execution slippage risks a distressed-strategy spiral.
What makes Gerresheimer unique
- Gerresheimer makes injectable-drug packaging and drug-delivery devices, not commodity bottles.
- Its 39-site footprint spans Europe, America, and Asia for local pharmaceutical supply.
- The July 2026 Apax sale accelerates focus on high-value injectable and medical-device businesses.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$518.8M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Flexible Work Hours
Wellness Program
Paid Vacation
Employee Discounts
Stock Price
Growth & Insights and Company News
6 month growth
↑ 18%1 year growth
↑ 18%2 year growth
↑ 18%Gerresheimer's business improves again, second half of year in focus. Published on 09/30/2026 at 05:30 am EDT dpa-AFX - Translated by Marketscreener - See original DUESSELDORF (dpa-AFX) - Business at packaging specialist Gerresheimer developed better in the second quarter than at the beginning of the fiscal year. According to preliminary calculations, the company generated revenue of €578m in the second fiscal quarter, which ended in May, €55m more than in the first three months, Gerresheimer said in Dusseldorf on Wednesday. Adjusted earnings before interest, taxes, depreciation and amortization rose by €35m from the previous quarter to €102m. However, revenue and operating profit declined compared with the year-earlier period. Business is expected to perform even better in the second half of the fiscal year. In addition, progress is being made on the agreed sales of the Centor and Primary Packaging Plastics divisions. The stock was recently up 3.5 percent. "Our gto transformation program is beginning to take effect," Chief Financial Officer Wolf Lehmann said. The sale of Centor is close to completion, while the divestment process for Primary Packaging Plastics is progressing swiftly and according to plan. Gerresheimer expects the second transaction to be completed in the first half of 2027. Gerresheimer plans to publish its final half-year report at the end of November. Gerresheimer is publishing its quarterly results late. The company postponed the release after investigations by Germany's Federal Financial Supervisory Authority, or BaFin, uncovered errors in its accounting. The Dusseldorf-based company subsequently had to restate its annual financial statements and tightened its accounting and control processes. There was also a change at the top of the company, along with the sale of business units. In April, the stock was removed from the SDax because the group failed to submit its 2024/25 annual report on time. The report has since been published, with Gerresheimer reporting a group loss of nearly €319m due to substantial impairments. The quarterly report for the first quarter has also already been released. Given the significant recovery in the share price, Gerresheimer is even being seen as having a chance of returning to the SDax soon./mne/mis/stk (C) dpa-AFX - 2026
Why is Gerresheimer stock rallying today? Published 08/27/2026, 04:07 AM (C) Reuters. Investing.com - Gerresheimer stock rallied 5.7% to reach €26.68 after the Düsseldorf-based pharmaceutical packaging specialist released preliminary fiscal first-quarter 2026 results, with the market focusing on a meaningful improvement in free cash flow and management's more optimistic tone regarding second-half performance. Revenue for the quarter came in at €524 million, edging up from €519 million in the comparable prior-year period on an adjusted basis, while adjusted EBITDA declined to €66 million from €81 million, with the margin narrowing to 12.6% from 15.7% - a trade-off the company framed as a deliberate strategic shift toward cash generation over near-term profitability. The results arrive against a backdrop of notable corporate turbulence. Just days earlier, on August 24, 2026, Gerresheimer confirmed an interim leadership change, with CEO Uwe Röhrhoff stepping down and Wolf Lehmann and Achim Schalk jointly assuming his responsibilities on a temporary basis. That transition, combined with an earlier reduction to the company's 2026 revenue guidance - pointing toward the lower half of the €2.3-€2.4 billion range - had kept the stock range-bound in the upper €20s for much of August. Today's cash flow signal appears to have provided the reassurance investors needed to re-engage with the shares. The broader market environment was supportive on the day, with U.S. equity indices posting gains and German mid-cap equities trading in positive territory, providing a constructive backdrop for a name like Gerresheimer, which is listed on the SDAX. The company operates in the specialized pharmaceutical and cosmetic packaging space, competing with peers in European healthcare packaging, and its focus on injectable drug delivery systems and self-administration devices ties its fortunes closely to long-term pharmaceutical demand trends. +0.930 (+3.68%) Real-time Data · 08:30:06 · EUR Taken together, the combination of better-than-feared cash flow dynamics in the preliminary Q1 figures, a stabilizing macro environment, and the market's relief that the new interim management team appears to be maintaining strategic continuity drove today's sharp recovery. The shares remain well below their 52-week high of €45.24, suggesting that while sentiment has improved, investors will be watching subsequent quarterly updates closely for evidence that the margin and cash flow trajectory is genuinely improving. Is your GXIG trade worth the risk? Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your GXIG chart and delivers a complete risk management plan - entry, stop-loss, and profit target - in under 60 seconds. Protect your downside. Validate every trade. Invest smarter.
Gerresheimer AG: Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG. EQS-News: Gerresheimer AG / Key word(s): Personnel Gerresheimer AG: Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG 24.08.2026 / 19:40 CET/CEST The issuer is solely responsible for the content of this announcement. Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG * Wolf Lehmann, CFO, and Achim Schalk, Member of the Management Board, will assume his duties until further notice Duesseldorf, August 24, 2026. Uwe Röhrhoff has stepped down from his role as interim CEO of Gerresheimer AG at his own request. He had assumed the position at the request of the Supervisory Board in November 2025, during a challenging period for the company. He had been appointed interim CEO of the company effective November 1, 2025, for a term ending no later than October 2026. During his tenure, together with his fellow Management Board members Wolf Lehmann and Achim Schalk - who were also newly appointed in 2025 - he succeeded in stabilizing the company and comprehensively addressing key issues. This includes the fact that, through the agreement signed at the end of July 2026 to sell the U.S. subsidiary Centor and the global Primary Packaging Plastics business, Gerresheimer will be able to significantly optimize its capital and financing structure and substantially reduce its leverage. Wolf Lehmann and Achim Schalk will assume his duties until further notice. "After successfully navigating the complex challenges of the past few months together with his colleagues on the Management Board, Mr. Röhrhoff has decided to step down from his role as interim CEO a few weeks before the end of his term," said Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG. "We respect his decision and would like to express our sincere gratitude for his tremendous dedication over the past few months, which reflects his commitment to Gerresheimer. Over the past few months, he has played a key role in bringing Gerresheimer back on a sustainable path for the future." About Gerresheimer Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Contact Gerresheimer | Media | / | | Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 [email protected] | Dersim Korkmaz Corporate Communication T +49 211 6181 296 [email protected] | | Investor Relations | / | | Guido Pickert Vice President Investor Relations T +49 211 6181 220 [email protected] | / | 24.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News | Language: | English | | Company: | Gerresheimer AG | | / | Peter-Müller-Str. 3 | | / | 40468 Duesseldorf | | / | Germany | | Phone: | +49-(0)211/61 81-00 | | Fax: | +49-(0)211/61 81-121 | | E-mail: | [email protected] | | Internet: | http://www.gerresheimer.com | | ISIN: | DE000A0LD6E6 | | WKN: | A0LD6E | | Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX | | LEI Code: | 5299006GD4UWSYZOKC28 | | EQS News ID: | 2387938 | | End of News | EQS News Service | 2387938 24.08.2026 CET/CEST
Gerresheimer selling two pharma packaging units in $1.7-Bn deals. Gerresheimer has agreed to sell two of its packaging units - Centor US Holding, which specializes in packaging systems for dispensing prescription drugs, and its global primary packaging plastics business - to an affiliate of funds advised by Apax Partners, a private equity firm, for EUR 1.5 billion ($1.7 billion). In 2025, the two businesses generated combined revenue of approximately EUR 570 million ($657 million) with a combined number of employees of approximately 2,400. The Centor facility is in Millersburg, Ohio, where the company manufactures packaging systems for prescription drug dispensing, including vials, plastic bottles, and closures. In addition to the Centor site in the US, the transaction includes a total of 15 production sites for primary plastic packaging in nine countries. "This transaction allows us to regain our strategic flexibility," explains Uwe Röhrhoff, CEO of Gerresheimer AG, in a July 29, 2026, statement in announcing the sale. "At the same time, as a leading global partner to the pharmaceutical and biotech industries, we are focusing our business even more strongly on high-value drug delivery and medical devices and primary packaging for injectable drugs." The purchase price for the two business units combined is based on an enterprise value of approximately EUR 1.5 billion ($1.7 billion). The parties have agreed not to disclose further terms of the agreements. The transactions are subject to customary closing conditions and approvals and will be closed independently of one another. The sale of Centor is expected to close by the end of financial year 2026, and the sale of the global primary packaging plastics business is expected to close in the first half of financial year 2027.
Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds. | EQS-Ad-hoc: Gerresheimer AG / Key word(s): Mergers and Acquisitions / Sale of Business Units/Strategic corporate decision Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds 29-Jul-2026 / 04:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds Duesseldorf, Germany, July 29, 2026. Gerresheimer Glass Inc., USA, Gerresheimer Glas GmbH, Gerresheimer Group GmbH and Gerresheimer AG ("Gerresheimer", ISIN: DE000A0LD6E6), today entered into definitive agreements with an affiliate of funds advised by Apax Partners LLP ("Apax Funds") regarding the sale of Centor US Holding Inc., USA, as well as Gerresheimer's global Primary Packaging Plastics (PPP) business. Under the terms of the agreements, Apax Funds will acquire from Gerresheimer a total of 15 production sites for primary packaging plastics in nine countries in addition to the production site of Centor in the USA. The purchase price for the two business units combined is based on an enterprise value of approximately EUR 1.5 billion. The parties have agreed not to disclose further details of the agreement. In 2025, Centor and Gerresheimer's Primary Packaging Plastics business generated combined revenue of approximately EUR 570 million with a total of around 2,400 employees. The transactions are subject to customary closing conditions and approvals and will be closed independently of one another. The sale of Centor is expected to close by the end of financial year 2026, while the sale of the global Primary Packaging Plastics business is expected to close in the first half of financial year 2027. Gerresheimer will use the expected cash inflows to significantly optimize its capital and financing structure by meaningfully decreasing its leverage. _______________________ End of inside information Contact Gerresheimer AG Investor Relations Guido Pickert Vice President Investor Relations T +49 211 6181 220 [email protected] Media Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 [email protected] End of Inside Information 29-Jul-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News | | Language: | English | | Company: | Gerresheimer AG | | / | Peter-Müller-Str. 3 | | / | 40468 Duesseldorf | | / | Germany | | Phone: | +49-(0)211/61 81-00 | | Fax: | +49-(0)211/61 81-121 | | E-mail: | [email protected] | | Internet: | http://www.gerresheimer.com | | ISIN: | DE000A0LD6E6 | | WKN: | A0LD6E | | Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX | | LEI Code: | 5299006GD4UWSYZOKC28 | | EQS News ID: | 2373112 | | End of Announcement | EQS News Service | 2373112 29-Jul-2026 CET/CEST
Gerresheimer is Hiring for 92 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Gerresheimer
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Düsseldorf, Germany
Founded
1864
Gerresheimer is Hiring for 92 Jobs on Simplify!
Find jobs on Simplify and start your career today